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Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the 
gastrointestinal tract from the mouth to anus. The cause of the disease is still unknown, 
but scientists have found various genetic mutations that are believed to play a role in the 
pathogenesis of the disease. One of these mutations include the NOD2 protein. Research 
has been conducted to shed light on the NOD2 signal transduction pathway and its 
involvement in NF-κB activation, a transcription factor that activates the production of 
various cytokines and chemokines that cause inflammation. By understanding this 
pathway and its relation to Crohn’s disease, drugs can be developed for more effective 
treatment. The general background of Crohn’s disease will be outlined including its 
symptoms, clinical features, epidemiology, and treatment. Chapter 2 is a literature review 
of research regarding the NOD2 pathway and the effects of NOD2 mutation in the 
activation of NF-κB. Finally, a model clinical case study will be reviewed in which the 
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CHAPTER 1  
A Review of the Clinical Features and Pathogenesis of Crohn’s Disease 
ABSTRACT 
 Crohn’s disease is a chronic inflammatory disease that affects the gastrointestinal 
tract. Its clinical features, symptoms, and pathogenesis are studied as well as its 
epidemiology, genetics, and the associated environmental factors. The diagnosis and 
different modes of treatment for Crohn’s disease are also discussed. Future directions in 




 Crohn’s disease is a type of Inflammatory Bowel Disease characterized by 
chronic inflammation that affects the gastrointestinal tract anywhere between the mouth 
and anus (Wilkins, Jarvis, & Patel, 2011). Inflammation is usually patchy and segmental 
and oftentimes involves the colon and terminal ileum (Mekhjian, Switz, Melnyk, Rankin, 
& Brooks, 1979; National Institutes of Health, 2009). In the 1979 study of 1,084 patients 
with Crohn’s disease, 55% of the patients presented with the disease in the colon and 
terminal ileum, 14% solely in the terminal ileum, 15% in only the colon, and 3% in other 
areas of the small intestine (Mekhjian et al., 1979).  
 Colonoscopy of Crohn’s disease patients can show skip lesions, cobblestoning, 
ulcerations, and strictures within the GI tract. The disease occurs transmurally and may 
span the whole thickness of the GI tract wall (Wilkins et al., 2011). This can lead to 
pathologic connections between the intestine and other areas of the digestive tract, 
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bladder, vagina, and skin which is associated with abscess formation. Patients may also 
experience gastrointestinal bleeding, abdominal masses, and anemia (National Institutes 
of Health, 2009). 
 The severity and activity of the disease may vary depending on its location. 
Symptoms are usually effectively controlled once diagnosed, but changes are likely to 
happen over time. After proper treatment, about 50% of patients go into remission or 
have mild disease over the following five years, 45% of patients in remission will go one 
year without relapsing, 35% will have only one or two relapses, and 11% will have 
chronically active Crohn’s. Relapse rates for patients in remission at one, two, five, and 
ten years are about 20%, 40%, 67%, and 76%, respectively (CCFA, 2011).  
  Complications from Crohn’s disease can arise. Ulcers caused by inflammation 
may lead to fistulas that form tunnels through the walls of organs or intestines. Cronic 
inflammation can cause bowel perforation after walls have been weakened and scarring 
can result in intestinal blocking by narrow strictures. In addition, abscesses may develop 
and patients can have problems with absorption and malnutrition (CCFA, 2011). 
 
Pathogenesis 
 While the exact cause and mechanism of Crohn’s disease is still unknown, 
research has shown that many aspects such as genetics, immunobiology, and 
environmental factors contribute to the complex development of the disease.  
The intestinal mucosa in healthy individuals is in a state of controlled 
inflammation. In this highly regulated homeostatic environment, only pathogens are able 
to trigger an immune response. Individuals with Crohn’s disease, however, have 
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abnormal immune responses to native bacteria which result in tissue damage and 
inflammation. Those with the disease are usually genetically susceptible and also exhibit 
a decrease in diversity of gut microbiota especially within the Firmicutes and 
Bacteroidetes phyla (Shanahan, 2002). 
 There are genetic mutations associated with Crohn’s disease that are hypothesized 
to play a role in its pathogenesis. One of these mutations occurs in the mucin gene, 
MUC1, which suggests a decrease in the mucous that provides protection for the layer of 
epithelial cells that line the gut (Baumgart & Sandborn, 2012). Other mutations involving 
the disruption of mucosal defense mechanisms have also been linked to Crohn’s disease. 
Mucous-coated epithelium with tight junctions can become leaky which then increases 
permeability of the lining. Luminal antigens are then more able to enter the lamina 
propria where there are many immune cells present (Baumgart & Sandborn, 2012). Other 
mucosal defense mechanisms that may be disrupted in Crohn’s disease include IgA 
secretion and defensins (Lashner, 2013).  
 There are also mutations in the NOD2/CARD 15 gene and the autophagy gene, 
ATG16L1, that are related to Crohn’s Disease (Lashner, 2013). NOD2 (nucleotide 
binding domain) mutations have been linked to a weakened inflammatory cytokine 
response and decrease in defensin production and secretion. Defensins are produced by 
Paneth cells and act as antibiotics within intestinal crypts. In addition, there is ineffective 
autophagy that can lead to a decrease in the exocytosis of secretory granules in Paneth 
cells. As a result, there are lower levels of defensins, lysozymes, and phospholipase A2. 
Studies have also shown that there is a connection with another pattern recognition 
receptor, Toll-like receptors (TLR), in Crohn’s disease. TLR2 and TLR4 expression is 
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increased in affected individuals and there is an exaggerated immune response (Baumgart 
& Sandborn, 2012; Lashner, 2013). 
 With the depression of defense mechanisms comes uncontrolled microbial growth 
within the GI tract. NF-kB-dependent genes are then stimulated to make pro-
inflammatory cytokines such as tumor necrosis factor-α (TNF- α), interleukin-1 (IL-1), 
and IL-6 as well as the chemokine IL-8 (Lashner, 2013). Crohn’s disease is also 
characterized by the rapid recruitment and inappropriate retention of leukocytes 
(Baumgart & Sandborn, 2012). 
 
Symptoms 
Patients with Crohn’s disease usually present with inflammatory-type symptoms 
including diarrhea, abdominal pain and cramping, weight loss, fever, fatigue, stomatitis, 
and anal fissures (Lashner, 2013). For cases in which Crohn’s disease was limited to the 
colon, lower GI bleeding, perianal complications, and fever were observed (Mekhjian et 
al., 1979). Along with some of these symptoms, children may also present with a stunt of 
growth or delay in puberty (Lashner, 2013). Other symptoms include mouth ulcers, 
swollen gums, constipation, sores or swelling in the eyes, and draining of pus, mucus, or 
stools from around the rectum (“Crohn’s disease: MedlinePlus Medical Encyclopedia,” 
2013).  
Patients may also experience symptoms outside of the digestive tract. Peripheral 
and axial arthritis along with other inflammation-related symptoms that affect the eyes, 
liver, bile ducts, and the skin, such as in erythema nodosum, may arise (Lashner, 2013; 




 Crohn’s disease is most commonly diagnosed in patients ages 20 to 30, but it can 
affect people of all ages including children. The disease is also more prevalent in women. 
Nearly 26 to 199 per 100,000 people are diagnosed with Crohn’s disease each year. 
When calculated from the 2003 census, there are 10,000 to 47,000 new cases of Crohn’s 
disease in the U.S. and Canada, and as many as 630,000 people are afflicted with the 
disease. Northern Europe, the United Kingdom, and North America have the highest 
reported cases (Loftus, 2004). Within  the U.S., whites and Ashkenazi Jews are at a 
higher risk for developing the disease (Lashner, 2013). Research has also shown that 
genetics may play a role in contracting Crohn’s disease because there is a 50-60% 
occurrence in identical twins (Loftus, 2004). 
 
Genetics 
 While the genetic implications of Crohn’s disease are not entirely clear, more 
studies are trying to achieve a better understanding of it. Research has shown that the 
disease is most likely polygenic and that the genetic component of Crohn’s comes in the 
form of genetic susceptibility factors. Within the IBD1 genomic region on the 
pericentromeric region of chromosome 16, mutations of the NOD2/CARD15 gene have 
been linked to Crohn’s disease. NOD proteins are cytosolic receptors that detect bacterial 
antigens. Specifically, NOD2 proteins are able to activate nuclear factor κB (NF-κB), an 
important transcriptional factor involved in the start of inflammatory responses 
(Shanahan, 2002).  
 Other susceptibility genes that increase the risk of developing Crohn’s include 
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those that code for the receptor of the IL-23 cytokine and ATG16L1, a protein associated 
with autophagy and other processes. There are a variety of other genes and genetic 
mutations that have been associated with Crohn’s and it is not likely that only one gene is 





 Environmental factors play an important role in the development of Crohn’s 
disease. This is demonstrated by the fact that less affected ethnic groups such as Asians 
and Hispanics along with immigrants from low incidence areas, who have moved to 
regions with high incidence, are now showing an increase in incidence rates (Baumgart & 
Sandborn, 2012). It is still unclear as to what triggers Crohn’s disease, but many studies 
have linked several different environmental factors to its development.  
Research has shown that smokers are more than twice as likely to contract 
Crohn’s disease and exposure to secondhand smoke during childhood can also increase 
the risk. In addition, smokers with Crohn’s disease are less likely to have pure 
inflammation and more likely to have the disease within their ileum. Those who continue 
to smoke are also more likely to need immunosuppressive therapy to control their 
symptoms and may have recurrent disease following surgical resection (Loftus, 2004). 
 Some studies have shown that diets high in sugar and fat have been associated 
with Crohn’s (Loftus, 2004). Other factors including the use of oral contraceptives, 
nonsteroidal anti-inflammatory drugs, and antibiotics may also slightly increase the 
probability of developing Crohn’s disease (National Digestive Diseases Information 
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Clearinghouse, 2011). An increased number of mucosal, enteric bacteria as well as the 
different types of it have also been associated with the disease. Crohn’s disease can also 
be frequently seen after infectious gastroenteritis and also among those who have been 
exposed to a lot of stress (Baumgart & Sandborn, 2012). 
 
Diagnosis 
 Crohn’s disease can be diagnosed by collecting a patient history and performing 
various tests. A mass or tenderness in the abdomen, skin rash, swollen joints, or mouth 
ulcers may be found upon physical examination. When laboratory tests are conducted, the 
results can show low albumin levels, a high sedimentation rate to confirm the presence of 
inflammation, fecal fat, low blood count, high white blood cell count, and abnormal liver 
blood tests. To eliminate other possible causes of a patient’s symptoms, a stool culture 
can be taken (“Crohn’s disease: MedlinePlus Medical Encyclopedia,” 2013). The 
presence of antibodies against the outer membrane porin of E. coli and S. cerevisiae may 
also indicate Crohn’s disease (Wilkins et al., 2011). 
 A variety of other diagnostic tests that directly examine or visualize the GI tract 
can also be performed. These tests include an MRI of the abdomen, capsule endoscopy, 
computed tomography (CT) enterography, and small bowel follow-through with barium. 
A colonoscopy with ileoscopy can also be used because it not only gives a direct view of 
the inflammation, fistula, or stricture of the terminal ileum and colon, but it also can 
obtain biopsies. These tests can be done either individually or in pairs. For active small 
bowel Crohn’s disease, pairing tests produced more accurate diagnosing results. For 
example, when both capsule endoscopy and colonoscopy with ileoscopy were performed, 
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the sensitivity was 100% with 57% specificity. Neutrophilic inflammation, noncaseating 
granulomas, Paneth cell metaplasia, and intestinal villi blunting can also be found 
through histology (Wilkins et al., 2011). 
  
Treatment 
 Treatment for Crohn’s is tailored to individual patients depending on the disease’s 
location, activity, severity, and complications. Since Crohn’s disease cannot be cured, 
treatment focuses on controlling symptoms, bringing about and sustaining remission, 
preventing complications, and improving the patient’s quality of life (“Crohn’s Disease,” 
2014; Wilkins et al., 2011). Medications are typically prescribed based on the patient’s 
symptoms, but they can include aminosalicylates to help control inflammation and 
corticosteroids to decrease inflammation along with the activity of the immune system. 
Immunomodulators can also be prescribed to reduce inflammation in the GI tract and 
help induce remission or cause some sort of response in those who have yet to respond to 
treatment. Biologic therapies are also used in order to decrease inflammation by 
neutralizing proteins made by the immune system. Mild pain medications and antibiotics 
can also help in preventing or treating infections and fistulas (“Crohn’s Disease,” 2014). 
 Patients are sometimes subjected to bowel rest during which they may only have 
clear liquids or no oral intake whatsoever. Almost 20% of Crohn’s patients will need 
surgery to treat fistulas, bowel obstructions, and excessive bleeding. This surgery can be 
a small bowel resection, subtotal colectomy, protocolectomy, or ileostomy (“Crohn’s 
Disease,” 2014). 
 A healthy, nutritional diet can also help in reducing Crohn’s symptoms. Making 
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dietary changes such as avoiding high-fiber foods, drinking more liquids, and eating 
smaller meals more often can be recommended (“Crohn’s Disease,” 2014). 
 
CONCLUSION 
 Crohn’s disease is steadily becoming a more common chronic illness. It seriously 
affects quality of life and due to its symptoms and tendency for remission, there has been 
a larger need for more information on the disease. It is important to find the cause and 
mechanism of the disease in order to create more effective therapies. In a 2006 
investigation, defective innate immunity has been identified in Crohn’s disease. This 
manifests itself in reduced neutrophil accumulation and IL-8 production (Marks et al., 
2006). The cause of this abnormality and its influence on the immune system are still 
unknown, but there are current research initiatives targeted to understanding the 
mechanism of Crohn’s from the microbial and genetic aspects of the disease.  
By gaining a better understanding of Crohn’s disease, better treatments of the 
disease can be developed that effectively reduce symptoms instead of promoting the 
underlying immune system deficiency. Marks et al. (2006) propose methods such as 
directly introducing IL-8 to lesions, administering agents that increase blood flow or 
vasodilation, or using proinflammatory drugs in order to heal or prevent lesions in 
Crohn’s disease patients.  
Other future directions for research include maintaining the health of the intestinal 
mucosal surface as well as establishing a detailed diagnosis and activity for Crohn’s 
disease in order for doctors to properly treat patients. Researchers are also looking into 
effectively modulating intestinal microbiota and the mucosal immune system to prevent 
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or control Crohn’s disease. In addition, the regeneration and repair of mucosal surface 
damage after inflammation and preventative measures to avoid Crohn’s disease are also 
being studied (National Institutes of Health, 2009). With all of the research advances 
being made every day, Crohn’s disease is becoming better understood and it is hoped that 











 Nucleotide-binding oligomerization domain-2 (NOD2) is an intracellular receptor 
that detects bacterial antigens. Mutations of the NOD2 protein have been associated with 
Crohn’s disease and identified as a susceptibility factor. Through its association with 
serine-threonine kinase RICK after the homophilic interaction of two capase recruitment 
domains (CARDs), NOD2 activates nuclear factor κβ (NF-κβ). The mutated version of 
NOD2 found in Crohn’s disease greatly stimulates NF-κβ activity and results in the 
production of proinflammatory cytokines. In this report, the signaling pathway of NOD2 
and the effects of a NOD2 mutation are examined. 
 
INTRODUCTION 
The pathogenesis of Crohn’s disease is complex and is still being extensively studied 
today. There are three elements that interact within the disease that contribute to its 
overall complexity: genetic susceptibility factors, priming by the enteric microflora, and 
tissue damage via the immune system (Shanahan, 2002). A mutation in the nucleotide-
binding oligomerization domain-2 (NOD2) gene is among the various genetic 
susceptibility factors related to Crohn’s disease that have been discovered.  
The NOD2 gene is found within the Inflammatory Bowel Disease 1 (IBD1) locus that 
is located on chromosome 16 (Shanahan, 2002). NOD2 consists of a nucleotide-binding 
domain (NBD), two N-terminal capase recruitment domains (CARDs), and 10 C-terminal 
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leucine-rich repeats (LRRs) (Ogura et al., 2001). It is expressed mainly in macrophages 
and dendritic cells and is involved in the pattern recognition of pathogens. NOD2 
recognizes the muramyl dipeptide (MDP) component of peptidoglycan (PGN), a 
component of bacterial cell walls (Hasegawa et al., 2008; Maeda et al., 2005). After 
recognition of MDP, NOD2 can activate nuclear factor κβ (NF-κβ), a transcription factor 
that activates different genes to produce various cytokines and chemokines including 
tumor necrosis factor α (TNF-α), interleukin-1β (IL1B), and interleukin-6 (IL6). The 
released cytokines that are produced after the activation of NF-κβ result in inflammation. 
When the cell is not stimulated, NF-κβ is bound to IκBα and IκBβ which prevent it from 
entering the nucleus (Barnes & Karin, 1997). IκB kinase (IKK) is a protein complex 
composed of IKKα, IKKβ, and IKKγ (NEMO), which regulates the inhibition of the IKK 
complex. Activated IKK complexes phosphorylate IκB subunits that bind to inactive NF-
κβ which results in these subunits’ degradation and the activation of NF-κβ (Karin, 
1999). 
Genetic factors play an important role in Crohn’s disease (Shanahan, 2002). Due to 
its connection with inflammation, NOD2 and any of the proteins involved in its 
downstream signaling pathway are potential targets for therapeutic drugs to treat Crohn’s 
disease. Understanding the importance and mechanism of NOD2 signaling in those 
affected and unaffected with Crohn’s disease can lead to potentially better drugs and 
overall insight on the pathogenesis of the disease. 
 This report is an overview of the specific mechanism of the NOD2 signaling 
pathway that utilizes the serine-threonine kinase RICK and results in the activation of 






 In order to observe the relationship between NOD2 with the IKK complex and 
RICK, NOD2 was cloned into DNA by polymerase chain reaction (PCR) (Ogura et al., 
2001). PCR consists of a series of heating and cooling steps with heat-stable DNA 
polymerase in order to clone the expression plasmid. The plasmids created included the 
variables being tested: FLAG-RICK, FLAG-IKKα and its mutant, IκBα, IKKβ and its 
mutant, and IKKγ. These cloned plasmids were then transfected into HEK293T cells 
along with the NOD2 plasmid that was produced. In the first experiment, these HEK293T 
cells were stimulated with 10 ng/ml of TNFα for 4 hours and 70 ng of mutant plasmids 
IκBα, IKKα, IKKβ, RICK, or RIP. For the experiments involving wild type (wt) RICK 
and NOD2 mutant proteins, HEK293T cells were cotransfected with pcDNA3-FLAG-
RICK and wt or mutant NOD2 expression plasmids. Anti-FLAG antibody was used to 
detect the proteins that were taken out of solution with anti-HA antibody via 
coimmunoprecipitation. For the experiment involving wt NOD2 and RICK mutants, 
HEK293T cells were cotransfected with HA-NOD2 and FLAG-RICK. The proteins were 
coimmunoprecipitated and detected in a similar fashion to the previous experiment 
(Ogura et al., 2001).  
 The NOD
22939iC
 mutation in the mice was done by first inserting an additional 
cytosine at position 2939 of mouse NOD2 via PCR. This caused as frame-shift mutation 
that led to a truncated NOD2 protein that is characteristic of human NOD2
3020iC
 which is 
associated with Crohn’s disease. The mouse NOD2
22939iC
 was inserted in a vector that 
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was then injected into C57BL/6 blastocysts. Male chimeras were crossed with C57BL/6 
females to produce heterozygous NOD2
+/22939iC
 mice that were interbred to produce 
homozygous mutant NOD2
22939iC
 mice (Maeda et al., 2005). 
The mouse studies concerning the physiological effects of the Nod
22939iC
 mutation 
in mice involved compromising the mucosal epithelial cells found in the mice’s colons—
an attribute found in Crohn’s disease patients. Both the wild type (wt) and the 
homozygous Nod
22939iC
 mice (8 to 12 weeks old) were given 3% dextran sodium sulfate 
(DSS) in drinking water for 6 days. DSS kills mucosal epithelial cells and disrupts their 
ability to act as a barrier, allowing bacteria to invade and come in contact with 
macrophages that reside in the lamina propria. Weight loss, an attribute of intestinal 
inflammation, was monitored. To obtain the histological and gene expression samples, 
the mice were killed either before or 11 days after the start of the DSS treatment (Maeda 
et al., 2005).  
 To study NF-κB activation in NOD2
2939ic
 mutated macrophages in MDP, bone 
marrow-derived macrophages (BMDMs) were cultured from DSS-treated NOD2
2939ic 
mice. They were then treated with various bacterial elements including MDP.  
 Binding activity of NF-κB to DNA was determined using an electrophoretic 
mobility shift assay (Maeda et al., 2005). NF-κB activity was determined through a series 
of transfections of reporter constructs. When the cell extracts were prepared, the relative 
luciferase activity was measured (Ogura et al., 2001). 
Many of the experiments conducted involved the use of the Western Blotting 
technique. In this technique, denatured proteins are applied to a gel and are separated by 
charge and size after a current is run through the gel. Once separation occurs, the samples 
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are transferred to another membrane where the pattern and location of the separated 
proteins are maintained. To quantify the separated protein, antibodies specific to the 
protein of interest are added to the membrane where they will bind to their target 
proteins. A modified secondary antibody is then added to the membrane where it will 
bind to the primary antibodies and allow for the visualization of the target protein (Maeda 
et al., 2005; Ogura et al., 2001). 
To visually analyze the colon samples, the colons were fixed in 10% formaldehyde, 
dehydrated, embedded in paraffin and cut into 5 μm sections. These sections then 
underwent deparaffinization, rehydration, treatment with 3% H2O2 in phosphate-buffered 
saline (PBS), and an overnight incubation period with anti-IL-6, anti-Cox-2, anti-F4/80, 
or isotype matched control antibodies of equal concentration. Anti-rabbit or anti-rat IgG 
antibodies labeled with biotin were used to detect the binding of primary antibody and 




 The connection between NOD2, IκB kinases (IKKs), and NF-κB was studied in 
the following experiment. NOD2 was coexpressed with mutant forms of IKKα, IKKβ, 
and IκB—all of which inhibit their equivalent within the cell and/or the IKK complex. 
Because the mutant forms of IKKα, IKKβ, and IKKγ (NEMO) have the ability to inhibit 
their counterparts within the actual cell, NF-κB activity induced by NOD2 was greatly 
inhibited (Figure 1A). The other two molecules being tested included a shortened form of 
RICK as well as a mutated receptor interacting RIP that expresses the death effector 
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domain of RICK. The mutated version of RICK, consisting of its CARD, was added in 
order to inhibit the NOD1 pathway and observe any NF-κB activation via NOD2. These 
were included in the experiment due to the downstream involvement of RICK’s within 
the signaling pathway (Ogura et al., 2001). 
 Figure 1A shows the low NF-κB activity induced by both NOD2 and TNF-α 
when coexpressed with all three dominant negative mutant forms of IKK. Additionally, 
NF-κB activity induced by NOD2 was inhibited by the RICK mutant but not by the RIP 
mutant.(Ogura et al., 2001) 
In Figure 1B, two different cell lines were tested to verify that NOD2 is an 
upstream regulator of the IKK complex in the activation process of NF-κB. Rat1 
fibroblasts and 5R cells, a Rat1 cell line lacking the regulatory IKKγ, were used in this 
study. NF-κB activity induced by NOD2, NOD1, and TNF-α was not inhibited in the 
Rat1 line but was inhibited in the 5R cells. IKKβ, a protein used downstream of IKKγ, 




Figure 1. NF-κB activity is a result of NOD2 interacting with the IKK complex. 
Dominant negative mutant forms of IKKα, IKKβ, and IκB were coexpressed with NOD2 
and the NF-κB activity was measured in triplicate using cultures of HEK293T cells 
(Figure 1A). Rat1 cells and 5R cells, which lacked IKKγ, were tested for NF-κB activity 
induced by NOD2, NOD1, TNFα, and IKKβ. The data is presented as percentages of the 





 From the previous experiment, it was noted that NF-κB activity induced by 
NOD2 was inhibited by the RICK mutant. To determine if RICK is a mediator of direct 
downstream NOD2 signaling and if physical association occurs between NOD2 and 
RICK, the HEK293T cells were cotransfected to express hemagglutinin-tagged (HA-
tagged) NOD2 and FLAG-tagged RICK. Anti-HA antibody immunoprecipitated cellular 
extracts in order to isolate the protein. These immunoprecipitations along with the 
immunoblot with anti-FLAG antibody showed association of both CARDs of NOD2 with 
RICK. 
 
Figure 2. Interaction of NOD2 with RICK. A and B show an interaction of wild type 
(wt) and mutant NOD2 with RICK. RICK was coimmunoprecipitated and 
immunoblotting with anti-FLAG antibody was used to probe for the protein (top panel). 
The blotting of total lysates is shown in the middle panel and NOD2 immunoprecipitates 
are in the bottom panel. In C, NOD2 interacted with wt and mutant RICK. NOD2 was 
coimmunoprecipitated and detected with anti-HA antibody via immunoblotting (top 
panel). Lysates were also probed with anti-HA (middle panel) and anti-FLAG (bottom 




To study the effects of a mutation in NOD2, the NOD2
2939ic
 mutation (m/m) was 
created. NOD2
2939ic
 is a mouse homolog of 3020insC, the most common Crohn’s disease 
susceptibility allele. The influence of a NOD2
2939ic 
mutation on NF-κB activation in bone 
marrow-derived macrophages (BMDMs) was examined in the following experiment. In 
Figure 3, BMDMs from wt and NOD2
2939ic
 homozygous mice were prepared by 
incubating the sample with MDP. Analysis showed that, as compared to the wt mouse, 
the m/m mouse showed an overall greater amount of IKK activation (KA), IκBα 
degradation, and NF-κB DNA binding activity. In addition, there was an increase in 









(m/m) BMDMs were incubated with 1 μg/ml MDP. Extracts from the 
cytosol and nucleus were analyzed for IKK activation (KA), IκBα degradation, and NF-




Figure 4. Increased expression of NF-κB target genes in Nod
22939iC
 macrophages 
treated with MDP. The graph shows the fold increase in mRNA expression of Nod
22939iC
 
macrophages in relation to wt macrophages. Wt macrophage mRNA expression was 
assigned an arbitrary number of 1.0 for each gene. The data is presented as the means of 
three experiments ± the standard error of the mean (SEM) (Maeda et al., 2005). 
 
 
In order to observe the physical effects of the Nod
22939iC
 mutation, wt and m/m 
mice were treated with DSS. The appearance of the colon and the tissue indicate greater 
inflammatory lesions and areas of ulceration in the colons of the mutant mice than in the 
wt mice (Figure 5). The activity of NF-κB DNA binding and IKK was also measured in 
the colonic mucosa of mice treated with DSS. The results show an overall increase in NF-
κB and IKK activity in Nod
22939iC





Figure 5. Inflammation of colon in DSS-treated Nod
22939iC
 mice. The top panels show 
the typical appearance of the colon in both wt and m/m mice 11 days after DSS 
treatment. The bottom panels show the histology of the colon tissue. The images are 
taken at 100x magnification and the arrows designate borders of ulcers (Maeda et al., 
2005). 
 
Figure 6. Increased NF-κB and IKK activity in DSS-treated Nod
22939iC
 mice. Nuclear 
and cytosolic extracts of colonic mucosa were prepared before DSS treatment and 11 
days after. These were analyzed for NF-κB DNA binding and IKK kinase (KA) activities 
using immunoblotting with antibody against histone deacetylase (HDAC) and antibody 





Nod2 acts through IKKα, IKKβ, and IKKγ to activate NF-κB. As seen in Figure 
1, the activation of NF-κB by NOD2 requires IKKγ and is inhibited by the dominant 
negative forms of IKKs and mutant RICK. The mechanism through which NOD2 
activates NF-κB involves a main signal transduction pathway mediated by IκB kinases 
(IKKs). The ability for the mutants IKKα, IKKβ, IKKγ, and IκBα to inhibit NF-κB 
activity induced by NOD2 shows the involvement of these molecules in the signaling 
pathway (Figure 1A). NOD2 also acts upstream of the IKK complex. This was verified 
when NF-κB activity, induced by NOD2, was observed in cells that contained IKKγ but 
was inhibited in cells that lacked IKKγ (Figure 1B).  
 In the NOD2 signaling mechanism, NOD2 interacts with RICK through a 
homophilic CARD-CARD association (Figure 2). The western blots in Figure 2A and 2B 
show that only NOD2 proteins with both CARDs have the ability to interact with RICK. 
This homophilic CARD-CARD interaction was determined in the results of Figure 2C. 
Only the CARD of RICK coimmunoprecipitated with NOD2. Having both CARDs 
present may improve the affinity of the CARD of RICK (Ogura et al., 2001). 
 The results from the experiments involving the NOD2
2939ic
 mutation (m/m) 
support the previous conclusions that NOD2 is involved in the activation of NF-κB. 
Figure 3 shows an increase in NF-κB DNA binding activity when NOD2
2939ic
 
macrophages were incubated with MDP. The blots also exhibit an increase in IKK 
activation (KA) which phosphorylates inhibitory IκBα and causes IκBα to dissociate 
from NF-κB. This increase in KA suggests the increase of NF-κB. There is also 
decreased IκBα in the m/m mouse indicating even less inhibition of NF-κB. With the 
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increase of NF-κB, there was a significant increase in the expression of NF-κB target 
genes when the NOD2
2939ic
 and wt macrophages were compared (Figure 4). Various pro-
inflammatory cytokines and inflammation related proteins including IL-6, TNF-α, and 
COX-2 were greatly upregulated in NOD2
2939ic
 macrophages. These results suggest that 
the NOD2 mutation results in an increase of NF-κB activity and, therefore, an increase in 
production of the cytokines and chemokines that cause inflammation. 
 The increase of NF-κB activity does, in fact, result in more inflammation. Figure 
6 shows a greater amount of NF-κB DNA binding activity in the colon tissue of 
NOD2
2939ic
 mice than in wt mice. The NOD2
2939ic
 mice also exhibited more colonic 
inflammation and larger ulcers than the wt mice (Figure 5). 
  The entire pathway of NOD2 activation of NF-κB is still not known. Topics such 
as the role of the LRR on NOD2 require more research (Ogura et al., 2001). In addition, 
NF-κB activation is not unique to NOD2 and its loss may not hinder NF-κB signaling in 
bacterial infection responses. To further study a potential target for drugs, the importance 




Crohn’s Disease: A Clinical Case Study 
Patient Introduction 
Isobel Clarke is a 23-year-old, Caucasian female who presents in the clinic with 
the chief complaint of having diarrhea, fatigue, intermittent fever and abdominal pain for 
the past three weeks.  
History of Present Illness 
Isobel explains that her symptoms began three weeks ago with what she thought 
was the stomach flu. She had a high fever, diarrhea, fatigue, and nausea for the first two 
days of her illness. On the third day, she felt reasonably better and returned to work. 
After a few days, she began experiencing diarrhea once more along with intermittent 
fever and abdominal pain. Isobel describes the abdominal pain as a dull, gradual ache that 
can last for up to an hour that comes and goes. She has been taking ibuprofen to ease 
fever chills and abdominal cramps when she experiences them. These symptoms have 
lasted for a month. 
As a new journalist at the local newspaper, she admits to being under a lot of 
pressure and stress. She has been feeling more fatigued as of late, has lost her appetite, 
and does not get much sleep when she has the chance. Since she began her job two 
months ago, Isobel has lost seven pounds. She also admits to not seeking medical 
attention until now due to her busy work schedule. When asked if this was her first time 
experiencing these symptoms, Isobel remembers having similar symptoms right before 
her final exams during a difficult semester her junior year of college. But the symptoms 




 Isobel has no history of any major illnesses, but has had eczema since she was a 
child. Her only major surgery has been the removal of her wisdom teeth at 18 under 
anesthesia. She is currently taking birth control as well as 400mg of ibuprofen when 
needed, but never exceeds 1.2g in one day. She has no known food allergies but is 
allergic to penicillin, the use of which results in a rash. Isobel drinks alcohol socially, but 
admits to drinking more frequently with friends since her job began. She denies the use of 
any recreational drugs or smoking. Her immunizations are up-to-date and include the Hep 
A, Hep B, and HPV vaccines.  
 Isobel graduated from Journalism school last year, moved out of her hometown, 
and started an internship in New York. After a year, she accepted an offer at her current 
workplace back in her hometown as a journalist and assistant editor. The hours are more 
strenuous than she anticipated and she has had trouble adjusting to the job. She initially 
thought her symptoms were a result of a very bad stomach flu, but the symptoms have 
lasted for a month. Isobel currently lives in an apartment with her childhood best friend 
and regularly visits her parents and siblings who still live in town. She is usually a very 
fit individual who enjoys working out and having an active lifestyle. She tries her best to 
make time for a workout three days a week to help relieve stress, but claims her tight 
schedule has caused her to choose fast, unhealthy food options if she has an appetite. Her 
sleep pattern has been erratic—Isobel usually gets an average of 5 hours of sleep a night. 
Since starting her new job, no matter how much time she sleeps, she never feels well-
rested in the morning. She is currently single, has had sexual intercourse, and is currently 
not sexually active.  
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 Her parents, Robert and Jane Clarke, are both 50 years old. Jane has no current 
illnesses, but Robert is currently taking medication for high blood pressure. There is 
history of hypertension on her father’s side; her paternal grandfather died of a heart attack 
at age 70. Her maternal grandmother has had breast cancer. Isobel has two younger 






Weight: 120 lbs 
BMI: 19.4 (Low normal) 
Body Temperature: 99.6°F 
Pulse: 100 BPM 
Respiration rate: 18 breaths/min 
Blood Pressure: 118/80mmHg 
General: 
23 yo female appears tired, haggard, and thin. She is alert and cooperative. 
HEENT: 
Head: Normocephalic, no tenderness. 
Eyes: Pupils equal, round, react to light and accommodate (PERRLA), 




Ears: Clear external auditory canals and tympanic membranes. Hearing intact. 
Nose: No nasal discharge, polyps, swelling, or septal deviation. 
Throat/Oral: Moist mucous membranes, oral cavity and pharynx normal. No 
inflammation, swelling, erythema, or exudates. 
Neck: Supple and non-tender. No thyromegaly, masses, or nodes. Negative Brudzinski 
and Kernig tests. 
Chest: Breathes easily with no wheeze, rales, rhonchi, or respiratory distress.  
CVS: Normal S1 and S2. Non-displaced point of maximal impulse (PMI). No murmurs, 
rubs, gallops, bruits, or thrills. 
Abdominal: Soft, tender, and slightly distended. Hyperactive bowel sounds. No masses 
or heptasplenomegaly (HSM).  
 Rectal Exam: No anal, perianal, or rectal lesions, fistulas, or fissures. 
Musculoskeletal: Adequately aligned and intact spine. No tenderness, spasms, or 
deformities. Normal range of motion (ROM), gait, and muscle development. No joint 
erythema or tenderness. 
Extremities: Moves all extremities (MAE) and full range of motion (FROM). No 
tenderness, edema, or varicosities. No deformities or joint abnormalities. Peripheral 
pulses intact. 
Skin: Very warm, dry, and pale. Mild eczema patches on arms that are roughly half an 
inch in diameter.  
Neurological: Speaks clearly and appropriately. CN II-XII intact, no facial droop or 






Test Result Reference Range 
Complete Blood Count (CBC) 
White Blood Cell (WBC) 12,000/ μL 4,000-10,000/μL 
Red Blood Cell (RBC) 3.2 x 10
6
/ μL 4.2-5.9 x 10
6
/μL 
Hemoglobin (HB/Hgb) 10 g/dL 12-16 g/dL 
Hematocrit (HCT) 30% 36-47% 
Mean Cell Volume (MCV) 93.75 fL 80-100 fL 
Mean Cell Hemoglobin (MCH) 31.25 pg 28-32 pg 
Mean Cell Hb Conc (MCHC) 33.33 g/dL 32-36 g/dL 
Platelet Count 400,000/μL 150,000-350,000/μL 
Mean Platelet Volume 8.0 fL 7.5-11.0 fL 
WBC Differential 
Neutrophil (Absolute) 8,400/μL  
Neutrophil (Relative) 70% 33-73% 
Lymphocyte (Absolute) 1,800/μL  
Lymphocyte (Relative) 15% 13-52% 
Monocyte (Absolute) 960/μL  
Monocyte (Relative) 8% 0-10% 
Eosinophil (Absolute) 600/μL  
Eosinophil (Relative) 5% 0-5% 
Basophil (Absolute) 240/μL  



















Test Result Reference Range 
Basic Metabolic Panel 
Glucose 80 mg/dL Fasting, 70-100 mg/dL 
Calcium 9.8 mg/dL 9-10.5 mg/dL 
Sodium 127 mcq/L 136-145 mcq/L 
Potassium 3.0  mcq/L 3.5-5.0 mcq/L 
Bicarbonate 19 mcq/L 23-28 mcq/L 
Chloride 85 mcq/L 98-106 mcq/L 
Blood Urea Nitrogen (BUN) 10 mg/dL 8-20 mg/dL 
Creatinine 0.9 mg/dL 0.7-1.3 mg/dL 
Erythrocyte Sedimentation Rate (ESR) 
 35 mm/hr <20 mm/hr 
C-Reactive Protein (CRP) 
 20 mg/L <10 mg/L 
Iron Studies 
Ferritin 189 ng/mL 15-200 ng/mL 
Iron 50 μg/dL 60-160 μg/dL 
Iron-binding capacity 480  μg/dL 250-460 μg/dL 
Transferrin saturation 17% 20-50% 
Vitamin B-12  
 150 pg/mL 200-800 pg/mL 
Liver Studies 
Alkaline phosphatase 45 U/L 36-92 U/L 
Aminotransferase, alanine 
(ALT) 
24 U/L 0-35 U/L 
Aminotransferase, aspartate 
(AST) 
17 U/L 0-35 U/L 
Bilirubin: Total 0.7 mg/dL 0.3-1.2 mg/dL 
Bilirubin: Direct 0 mg/dL 0-0.3 mg/dL 
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Figure 7. Colonoscopy with ileoscopy results. Abnormalities found in terminal ileum 
including “cobblestoning” and inflammation of mucosa. No fistulas, ulcers, polyps, or 






































Figure 8. Upper GI Series with Small Bowel Follow-Through (UGI w/ SBFT). 
Patient image shows narrowing of the terminal ileum and thickening of the mucosal wall. 
No other abnormalities were found in the UGI of SBFT (Austen & Lieberman, 2001). 
 
 
Diagnosis and Supporting Argument  
 
Isobel has been diagnosed with Crohn’s disease and anemia based on her physical 
exam, history, lab results, and endoscopic findings. The diarrhea, abdominal pain, low 
grade fever, and weight loss she is experiencing are characteristic symptoms of Crohn’s 
disease. Crohn’s is a chronic inflammatory disease that can be found anywhere along the 
gastrointestinal tract. The patient’s high WBC count, ESR, and CRP are indicative of 
inflammation. Isobel has been experiencing her symptoms for a month now and an 








information, it is likely Isobel is suffering from a chronic illness. Her lack of sleep, long 
work hours, and constant stress may have also contributed a flare up of Crohn’s.  
The endoscopic tests reveal the most information about her condition. The results 
of the colonoscopy with ileoscopy showed a thickened mucosal wall with inflamed tissue 
that was patchy and discontinuous (“cobblestone” appearance) in the terminal ileum. 
These findings, along with the narrowing of the terminal ileum, are typical attributes of 
Crohn’s disease. In fact, 35% of Crohn’s patients experience inflammation within the 
ileum (Lashner, 2013; Wilkins et al., 2011). A biopsy of the affected area in the terminal 
ileum demonstrated full-thickness inflammation, another characteristic of Crohn’s.  In 
addition, the patient’s lab results show low values for RBC count, hemoglobin, 
hematocrit, iron, and vitamin B-12. These are symptoms of anemia, another illness 
associated to Crohn’s disease, and explain the patient’s extreme fatigue and fast heart rate 
(Joseph E Maakaron, 2014; Wilkins et al., 2011).  
The patient’s stool culture was negative, making the diagnoses of any bacterial or 
parasitic infection less likely. Irritable Bowel Syndrome (IBS) can be ruled out since 
Isobel does not complain of painful bowel movements and her symptoms of weight loss, 
fever, and painless diarrhea are inconsistent with IBS. Typically patients with IBS have 
diarrhea immediately after eating along with abdominal pain that disappears following a 
bowel movement (Jenifer K Lehrer, 2015). From the rectal exam and the colonoscopy 
with ileoscopy, no suspicious lesions or polyps were found, making colorectal cancer 
unlikely (Dragovich, 2014). The patient does not have Ulcerative Colitis (UC) because 
her stools are not bloody and the affected region is the terminal ileum, whereas in UC, 
only the colon is involved. In addition, the biopsy from the colonoscopy with ileoscopy 
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revealed transmural involvement while in UC, only the mucosa and submucosa are 
affected. The liver function test shows the patient does not have sclerosing cholangitis, a 
disease that can be caused by Crohn’s (Wilkins et al., 2011). 
 
Treatment Plan 
 The goals of Isobel’s treatment for Crohn’s disease is to manage her symptoms, 
induce remission, maintain remission, and improve quality of life (Wilkins et al., 2011). 
For her moderate to severe symptoms, corticosteroids were prescribed. She will begin 
treatment with 40 mg of prednisone daily until her symptoms improve and remission is 
induced (Irving & Gibson, 2008). At the point that her symptoms subside, her medication 
will be gradually lowered until she is weaned off prednisone. In addition, the patient will 
need to take iron and B-12 supplements in order to treat her anemia. Increasing her 
calcium intake and taking vitamin D are also suggestions since she will be taking 
corticosteroids (Mayo Clinic Staff, 2014). Isobel will need to stop taking ibuprofen as 
studies have shown that nonsteroidal anti-inflammatory drugs may cause flares of 
Crohn’s (Beth Israel Deaconess Medical Center: Digestive Disease Center, 2015). 
It is recommended that Isobel be more conscious of her nutrition because a good 
diet can help relieve her symptoms of diarrhea and abdominal pain. This means eating a 
healthy, balanced diet, eating small portions throughout the day, drinking more water, 
and avoiding greasy, spicy, and fatty foods. It is also recommended that she limit her 
alcohol consumption and avoid foods with high fiber to prevent blocking in her inflamed 
and narrowed terminal ileum (A.D.A.M, 2012). 
Isobel will be referred to a gastroenterologist for further consultation. Once Isobel 
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is in remission, she will be weaned off the corticosteroid and take immunomodulators to 




 Crohn’s disease is a chronic illness that cannot be cured. Flare ups may occur 
intermittently, so many patients are treated long-term in order to maintain remission. 
Isobel will require periodic checkups in order to monitor her disease and prevent 
complications associated with Crohn’s. These complications include small bowel 
obstruction, fistulae, cancer, osteoporosis, and issues involving areas outside of the GI 
system like the joints and liver. Prednisone induces remission in 70-80% of patients and 
Isobel may even see her symptoms begin to resolve in a week. About 75% of Crohn’s 
patients will need surgery during the course of their disease. These surgeries are usually 
related to fistulas or bowel obstruction. Crohn’s disease is not fatal, but mortality rates in 
those affected are slightly higher than those who do not have the disease (Beth Israel 
Deaconess Medical Center: Digestive Disease Center, 2015). 
 
Plan Implementation 
 Isobel will need to take time from work in order to attend regular appointments 
with her gastroenterologist and primary physician. Regular follow ups will track her 
progress and will help promote remission. Isobel is encouraged to not let Crohn’s disease 
prevent her from doing the things she enjoys. She should get back to her normal exercise 
regimen, continue to visit her family often, and get a full night’s sleep in order to reduce 
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stress. Though it may be hard, Isobel must prioritize her health over her job. 
 Crohn’s disease may put a financial strain on Isobel and her family. Many of the 
drugs are very expensive, including the immunomodulators she will need to take once in 
she is in remission. The Crohn’s and Colitis Foundation of America website (ccfa.org) 
provides information about financial support. There are various other resources available 
on the website for Isobel to learn more about her disease.  
Her family and friends will provide a healthy support system as she learns to live 
with her disease. There are various support groups she can join in order to learn more 
about living with Crohn’s and be among peers going through the same issues. Due to her 
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